Pathogenetic base for a new approach in the treatment of diseases of the digestive system upper departments

T. I. Vlasova; E. V. Kondyurova; V. I. Davydkin; A. P. Vlasov; N. S. Sheyranov; V. V. Vasilyev; E. A. Mitina; K. M. Sinyavina

doi:10.31146/1682-8658-ecg-164-4-27-32

Pathogenetic base for a new approach in the treatment of diseases of the digestive system upper departments

T. I. Vlasova, E. V. Kondyurova, V. I. Davydkin, A. P. Vlasov, N. S. Sheyranov, V. V. Vasilyev, E. A. Mitina, K. M. Sinyavina

https://doi.org/10.31146/1682-8658-ecg-164-4-27-32

Full Text:

PDF (Rus) |

Generate QR code

Abstract

Two groups of patients with chronic severe periodontitis and gastropathy: І (comparison group, n = 26) - under standard therapy; ІІ group (studied group, n = 22) - Remaxol is included in the standard treatment regimen. On admission and after 10 days of treatment, we studied the structural and functional state of periodontal tissues with the calculation of clinical indices, performed fibrogastroduodenoscopy with a biopsy of the gastric mucosa, followed by determination of lipid composition in its tissues and red blood cells, determined the content of H. Pylori, pepsinogen I and II, immunoglobulin A and E, malonic dialdehyde and diene conjugates, the activity of phosphalipase A2 and catalase. Chronic periodontitis was established to be accompanied by significant structural and functional lesions of the stomach (gastritis, erosion, ulcers). The role of membrane-destabilizing phenomena in epithelial cells of the gastric mucosa has been proved in the pathogenesis of gastropathy. Oxidative stress and phospholipase activity are involved in the development of these phenomena. The use of Remaxol in the treatment leads to a decrease in inflammatory necrotic processes in the mouth and stomach. The effectiveness of the drug is largely due to its ability to reduce membrane-destabilizing processes by decreasing the activity of lipoperoxidation and phospholipase A2, as well as reducing the acidity of gastric juice.